Citadel Advisors
LJPC

Citadel Advisors’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Citadel Advisors’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-50,873
Closed -$217K – 14948
2022
Q1 		$217K Sell
50,873
-11,104
-18% -$48.4K ﹤0.01% 11337
2021
Q4 		$288K Buy
61,977
+34,759
+128% +$145K ﹤0.01% 11020
2021
Q3 		$109K Buy
27,218
+8,251
+44% +$32.8K ﹤0.01% 12777
2021
Q2 		$81K Buy
+18,967
New +$81.3K ﹤0.01% 13076
2021
Q1 		– Sell
-11,801
Closed -$65K – 14138
2020
Q4 		$46K Sell
11,801
-10,106
-46% -$43.2K ﹤0.01% 10597
2020
Q3 		$88K Sell
21,907
-15,288
-41% -$63.3K ﹤0.01% 9352
2020
Q2 		$158K Sell
37,195
-12,487
-25% -$76K ﹤0.01% 8710
2020
Q1 		$209K Buy
49,682
+18,696
+60% +$118K ﹤0.01% 7945
2019
Q4 		$122K Buy
30,986
+1,593
+5% +$9.41K ﹤0.01% 8468
2019
Q3 		$259K Buy
29,393
+14,893
+103% +$141K ﹤0.01% 7784
2019
Q2 		$134K Buy
+14,500
New +$109K ﹤0.01% 8411
2019
Q1 		– Sell
-106,273
Closed -$692K – 10439
2018
Q4 		$1M Buy
+106,273
New +$1.6M ﹤0.01% 5305
2018
Q3 		– Sell
-56,235
Closed -$1.47M – 10182
2018
Q2 		$1.64M Buy
56,235
+26,329
+88% +$813K ﹤0.01% 4408
2018
Q1 		$891K Buy
+29,906
New +$964K ﹤0.01% 4994
2017
Q3 		– Sell
-299,290
Closed -$9.62M – 8616
2017
Q2 		$8.91M Buy
299,290
+71,210
+31% +$2.04M 0.01% 1549
2017
Q1 		$6.81M Buy
+228,080
New +$5.82M 0.01% 1739
2016
Q1 		– Sell
-36,452
Closed -$650K – 9359
2015
Q4 		$984K Sell
36,452
-32,458
-47% -$885K ﹤0.01% 3595
2015
Q3 		$1.92M Buy
+68,910
New +$2.17M ﹤0.01% 3002

Other funds holding LJPC

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KT
Kevin Tang $783 AUM 75.59% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Citadel Advisors's LJPC Position: Q2 2022 in Review

Citadel Advisors sold out of La Jolla Pharmaceutical Company (LJPC) in Q2 2022, closing a stake of 50,873 shares — an estimated $217K sold.

Citadel Advisors first reported a position in LJPC in Q3 2015 and held it in 18 quarters. The position peaked at $8.91M in Q2 2017. 41 funds tracked by Wall St. Rank hold LJPC as of Q2 2022.

  • Citadel Advisors reported no remaining La Jolla Pharmaceutical Company position as of Q2 2022 after selling out during the quarter.
  • Citadel Advisors sold 50,873 La Jolla Pharmaceutical Company shares in Q2 2022, an estimated $217K.
  • Citadel Advisors first reported a position in La Jolla Pharmaceutical Company in Q3 2015 and held it in 18 quarters.
  • Citadel Advisors's La Jolla Pharmaceutical Company position peaked at $8.91M in Q2 2017.
  • 41 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q2 2022.

Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.